CEP290 and Leber congenital amaurosis: EDIT-101 (Editas Medicine, Massachusetts, USA) is a CRISPR-Cas9 based therapy targeting CEP290:c.2991+1655 A > G variant and commonly found in LCA patients of European ancestry [49]; however, the presence of this variant has not been identified in Chinese, Japanese, or Korean cohort studies [50].